PlumX Metrics
Embed PlumX Metrics

Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer

Cancers, ISSN: 2072-6694, Vol: 11, Issue: 6
2019
  • 78
    Citations
  • 0
    Usage
  • 149
    Captures
  • 1
    Mentions
  • 4
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    78
  • Captures
    149
  • Mentions
    1
    • News Mentions
      1
      • News
        1
  • Social Media
    4
    • Shares, Likes & Comments
      4
      • Facebook
        4

Most Recent News

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

Introduction Breast cancer is a heterogeneous disease with distinct subgroups categorized according to the expression level of estrogen receptor (ER), progesterone receptor (PR), and human

Review Description

An estimated 15-20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer. Neratinib, a next-generation, irreversible pan-HER TKI, is used in the US for extended adjuvant treatment of adult patients with early-stage HER2+ breast cancer following 1 year of trastuzumab. In Europe, neratinib is used in the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2+ breast cancer who are less than 1 year from the completion of prior adjuvant trastuzumab-based therapy. Preclinical studies have shown that these agents have distinct properties that may impact their clinical activity. This review describes the preclinical characterization of lapatinib and neratinib, with a focus on the differences between these two agents that may have implications for patient management.

Bibliographic Details

Collins, Denis M.; Conlon, Neil T.; Kannan, Srinivasaraghavan; Verma, Chandra S.; Eli, Lisa D.; Lalani, Alshad S.; Crown, John

MDPI AG

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know